Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 21

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 21
---
 valuation report, please see page 31.

Overview of the Merger Agreement and Agreements Related to the Merger Agreement

Merger Consideration and Exchange Ratio (see page 39)

Pursuant to the Merger Agreement, at the Effective Time, each share of TELI Common Stock outstanding immediately prior to the Effective Time will be automatically converted solely into the right to receive the number of shares of TELO Common Stock as determined by the Exchange Ratio, but in no instance will the amount of TELO Common Stock issued be greater than the number of outstanding TELO Common Stock as-of the closing date of the Merger.

| 9 |

No fractional shares of TELO Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of TELO Common Stock that a holder of TELI Common Stock would otherwise be entitled to receive will be aggregated with all fractional shares of TELO Common Stock issuable to such holder and any remaining fractional shares will be rounded up to the nearest whole share.

The Exchange Ratio is based upon a TELI valuation of $126.8 million and a TELO valuation of $101.1 million, as determined by Moore. For a summary of Moore’s fairness opinion and valuation report, please see page 31. Immediately following the Merger, the pre-Merger equity holders of TELO are expected to hold approximately 50% of the outstanding shares of TELO Common Stock and the pre-Merger equity holders of TELI are expected to hold approximately 50% of the outstanding shares of TELO Common Stock , on a non-diluted basis, and not including the issuance of the Warrants (as defined below).

For a more complete description of the Merger, the potential adjustments in the Exchange Ratio and the calculation of TELO’s net cash, please see the section titled “ The Merger Agreement —Merger Consideration and Exchange Ratio.”

Treatment of TELI Stock Options

TELI currently has no stock options outstanding.

Treatment of TELI Warrants

In addition to the shares of TELO Common Stock that will be exchanged for shares of TELI Common Stock at the Closing, Erez Aminov and Bayshore Trust, shareholders certain members of TELI, collectively hold 4,250,000 and 10,000,000 warrants, respectively, to purchase a total of 14,250,000 TELI Common Stock (the “Warrants”).